Guardant Health Inc. Common Stock (GH)

FairStock Score: 41/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach Guardant Health as a Graham-style skeptic. The company sells liquid and tissue biopsies and data sets for precision oncology; revenue is real and growing. In FY2025, it reported revenue of $982.0 million, up from $739.0 million in FY2024 and $563.9 million in FY2023. In the latest filed quarter, fiscal Q2 2026, revenue was $335.0 million versus $232.1 million in fiscal Q2 2025. That is impressive demand. But the bottom line remains poor. Net loss was $416.3 million in FY2025, after $436.4 million in FY2024 and $479.4 million in FY2023. In fiscal Q2 2026, the net loss was $120.1 million, worse than the $99.9 million loss in fiscal Q2 2025. Trailing free cash flow is negative $240.7 million. FairStock's calculations at the 2026-10-13 close show a market cap of $21.8 billion, a negative P/E of -46.31, ROCE of -18.07%, FCF yield of -1.1%, Piotroski F-Score of 4/9, and FairStock Score of 21/100. The Lynch category is 'none' because the company lost money in each of the last four years. A moat may exist in oncology testing know-how and data, but the financials do not yet prove durable pricing power or capital discipline. At roughly 22 times FY2025 revenue, the price discounts a lot of future success. I would want evidence of narrowing losses and positive cash generation before calling this a value investment. Until then, it is a speculative growth story, not a Graham bargain.

In plain English: Guardant Health sells blood and tissue tests that help doctors profile cancer and guide treatment. Sales are growing quickly, but the company still loses money and burns cash, so the business is not yet self-funding. At the latest close, its $21.8 billion value looks expensive compared with current sales and lack of profits, leaving little room for disappointment.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer